Walgreens tops estimates as drugstore chain cuts costs, prepares to go private

A sign for US drugstore chain Walgreens is displayed outside its store in New York City on March 7, 2025.

Angela Weiss | AFP | Getty Images

Walgreens on Tuesday reported fiscal second-quarter earnings and revenue that topped expectations, as the retail drugstore giant benefits from cost cuts and prepares to go private.

The company is in the process of being taken private by Sycamore Partners in a deal that is expected to close in the fourth quarter of this year.

Here’s what Walgreens reported for the three-month period ended Feb. 28 compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

Earnings per share: 63 cents adjusted vs. 53 cents expected
Revenue: $38.59 billion vs. $38 billion expected

This story is developing. Please check back for updates.

Source

The million Trump Card faces legal challenges, limited market

Business

The $5 million Trump Card faces legal challenges, limited market

June 26, 2025

U.S. President Donald Trump holds “The Trump Card” as he speaks with journalists onboard Air Force One en route to Miami, Florida, U.S., April 3, 2025. Kent Nishimura | Reuters A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to […]

Business

Nike will report earnings after the bell. Here’s what Wall Street expects

June 26, 2025

A shopper walks past a Nike store, as global markets brace for a hit to trade and growth caused by U.S. President Donald Trump’s decision to impose import tariffs on dozens of countries, in the King of Prussia Mall in King of Prussia, Pennsylvania, U.S., April 3, 2025. Rachel Wisniewski | Reuters Nike is expected […]

Business

RFK Jr.’s CDC vaccine panel backs Merck RSV shot for infants

June 26, 2025

Nikos Pekiaridis | Nurphoto | Getty Images Robert F. Kennedy Jr.’s revamped government panel of outside vaccine advisors on Thursday recommended the use of Merck‘s shot to protect infants from respiratory syncytial virus, a temporary reprieve for public health officials and companies concerned about the Health and Human Services secretary’s immunization policy. The group, called […]